JR-171 (lepunafusp alfa)
Phase 1/2Completed 0 watching 0 views this week⚡ Active
40
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis I
Conditions
Mucopolysaccharidosis I
Trial Timeline
Sep 1, 2020 → Aug 2, 2022
NCT ID
NCT04227600About JR-171 (lepunafusp alfa)
JR-171 (lepunafusp alfa) is a phase 1/2 stage product being developed by JCR Pharmaceuticals for Mucopolysaccharidosis I. The current trial status is completed. This product is registered under clinical trial identifier NCT04227600. Target conditions include Mucopolysaccharidosis I.
Hype Score Breakdown
Clinical
13
Activity
8
Company
9
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04227600 | Phase 1/2 | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis I